相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase
Rodrigo F. Ortiz-Meoz et al.
CHEMBIOCHEM (2021)
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Benjamin A. Gartrell et al.
INVESTIGATIONAL NEW DRUGS (2021)
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
Peter Kalev et al.
CANCER CELL (2021)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
Aaron Balog et al.
MOLECULAR CANCER THERAPEUTICS (2021)
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies
Sruthy Varghese et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Neural signaling modulates metabolism of gastric cancer
Hanne-Line Rabben et al.
ISCIENCE (2021)
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
Padma Kadiyala et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Lipid signalling enforces functional specialization of Treg cells in tumours
Seon Ah Lim et al.
NATURE (2021)
Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma
Man Hsin Hung et al.
NATURE COMMUNICATIONS (2021)
Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas
Aaminah Khan et al.
NATURE COMMUNICATIONS (2021)
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
Zenon Konteatis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo plus cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients ( pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
Nizar M. Tannir et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Gerald Falchook et al.
ECLINICALMEDICINE (2021)
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma
Atreyi Dasgupta et al.
CANCER RESEARCH (2021)
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer
Jeanetta Stega et al.
INVESTIGATIONAL NEW DRUGS (2020)
LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation
Keitaro Hayashi et al.
ALLERGY (2020)
Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation
Danay Cibrian et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Yukino Machida et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
Mounia Beloueche-Babari et al.
BRITISH JOURNAL OF CANCER (2020)
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis et al.
BRITISH JOURNAL OF CANCER (2020)
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
Justin A. Caravella et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors
Naohiro Okano et al.
INVESTIGATIONAL NEW DRUGS (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
Dawei Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation
Elisa Caiola et al.
CELLS (2020)
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Min-Hee Oh et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma
Ming Li et al.
CANCER RESEARCH (2020)
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
Erik L. Brincks et al.
Oncotarget (2020)
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
Ryan C. Augustin et al.
CANCERS (2020)
In vitro and in vivo anticancer effects of D/L-alpha-metyrosine (SM-88), a novel metabolism-based therapy
Alexander Vandell et al.
CANCER RESEARCH (2020)
Uncovering metabolic bottlenecks in KEAP1 mutant lung cancer
Sarah E. LeBoeuf et al.
CANCER RESEARCH (2020)
Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade
Yumi Yokoyama et al.
CANCER RESEARCH (2020)
Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH2O3
Naohiro Okano et al.
IN VIVO (2020)
Metabolism of immune cells in cancer
Robert D. Leone et al.
NATURE REVIEWS CANCER (2020)
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway
Lisha Du et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
IDO1 Inhibition Overcomes Radiation-Induced Rebound Immune Suppression by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Ailin Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma
Alex B. Blair et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
Marcus Smith Noel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor-Targeted Delivery of 6-Diazo-5-oxo-L-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs
Lukas Tenora et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Xiaoyun Li et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M. Fischer et al.
CANCER DISCOVERY (2019)
Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation
Andreas Weigert et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2019)
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma
Ana Galan-Cobo et al.
CANCER RESEARCH (2019)
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
Bethany C. Prudner et al.
CLINICAL CANCER RESEARCH (2019)
Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells
Larissa Menezes dos Reis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy
Hua Huang et al.
NANO LETTERS (2019)
The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer
Xinjie Lu
CURRENT CANCER DRUG TARGETS (2019)
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas
Philip A. Philip et al.
FUTURE ONCOLOGY (2019)
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study
Timothy S. Pardee et al.
FUTURE ONCOLOGY (2019)
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
Makoto Nakagawa et al.
ONCOGENE (2019)
719PPhase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients
A Ocean et al.
ANNALS OF ONCOLOGY (2019)
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Robert D. Leone et al.
SCIENCE (2019)
Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma
Kosuke Higuchi et al.
SCIENTIFIC REPORTS (2019)
Hyperpolarized C-13 MRI: Path to Clinical Translation in Oncology
John Kurhanewicz et al.
NEOPLASIA (2019)
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S. Heist et al.
MOLECULAR CANCER THERAPEUTICS (2019)
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 National Harbor, MD, USA. 6-10 November 2019
Zehui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
Christian R. Hoerner et al.
KIDNEY CANCER (2019)
Glutaminase inhibition in renal cell carcinoma therapy
Aleksandra M. Raczka et al.
CANCER DRUG RESISTANCE (2019)
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Timothy S. Pardee et al.
CLINICAL CANCER RESEARCH (2018)
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
Lingjun Zhang et al.
CLINICAL CANCER RESEARCH (2018)
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Jennifer R. Molina et al.
NATURE MEDICINE (2018)
Antagonism of PPAR-γ signaling expands human hematopoietic stem and progenitor cells by enhancing glycolysis
Bin Guo et al.
NATURE MEDICINE (2018)
Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
Yuki Egawa et al.
PLOS ONE (2018)
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
Micah T. Nelp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy
Adam J. Wolpaw et al.
TRENDS IN CELL BIOLOGY (2018)
Dipeptide Prodrugs of the Glutamate Modulator Riluzole
Jeffrey C. Pelletier et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model
Pascal Hafliger et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
We're Not DON Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
Kathryn M. Lemberg et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'
George C. Prendergast et al.
TRENDS IN CANCER (2018)
Methionine and methionine sulfoxide treatment induces M1/classical macrophage polarization and modulates oxidative stress and purinergic signaling parameters
Lien M. dos Santos et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2017)
Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer
Rahul Aggarwal et al.
EUROPEAN UROLOGY (2017)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Rodrigo Romero et al.
NATURE MEDICINE (2017)
Inhibition of L-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment
Supak Yothaisong et al.
TUMOR BIOLOGY (2017)
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Young Shin Cho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity
Nicola J. Curtis et al.
ONCOTARGET (2017)
Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression
Anke Werner et al.
FRONTIERS IN IMMUNOLOGY (2017)
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
Susanne M. Steggerda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
Timothy S. Heuer et al.
EBIOMEDICINE (2017)
CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines
K. L. Hippen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
Carolyn D. Britten et al.
CLINICAL CANCER RESEARCH (2017)
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Alessia Angelin et al.
CELL METABOLISM (2017)
Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640
Timothy S. Heuer et al.
CANCER RESEARCH (2016)
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Nicole E. Scharping et al.
IMMUNITY (2016)
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
Hao-Yuan Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
Omran Abu Aboud et al.
MOLECULAR CANCER THERAPEUTICS (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre et al.
ONCOTARGET (2016)
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Shiran Rabinovich et al.
NATURE (2015)
Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
Richard Ventura et al.
EBIOMEDICINE (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Radoslaw Polanski et al.
CLINICAL CANCER RESEARCH (2014)
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Matt I. Gross et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
Rebecca Lamb et al.
ONCOTARGET (2014)
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Paul M. Bingham et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Shawn D. Stuart et al.
CANCER & METABOLISM (2014)
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate
Sarah J. Nelson et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Christopher G. Duncan et al.
GENOME RESEARCH (2012)
Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development
Gerritje J. W. van der Windt et al.
IMMUNITY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Zuzana Zachar et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Otto Warburg's contributions to current concepts of cancer metabolism
Willem H. Koppenol et al.
NATURE REVIEWS CANCER (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
l-Type amino acid transporter 1 inhibitors inhibit tumor cell growth
Koji Oda et al.
CANCER SCIENCE (2010)
Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
Kevin J. French et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
PC Rodriguez et al.
CANCER RESEARCH (2004)
Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress
L Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
